Vaccination for the paediatrician

Journal of Paediatrics and Child Health

Volumn 42, Issue 11, 2006, Pages 665-673

  Wood, Nicholas ^a,c   McIntyre, Peter ^a   Wong, Melanie ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

Author keywords

AEFI; Immunodeficiency; Immunological and biological factor; Vaccination; Vaccine

Indexed keywords

ACELLULAR VACCINE; AZATHIOPRINE; BCG VACCINE; BIOLOGICAL FACTOR; CHICKENPOX VACCINE; CORTICOSTEROID; CYCLOSPORIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PREDNISOLONE; TACROLIMUS; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; VIRUS VACCINE; YELLOW FEVER VACCINE;

AUSTRALIA; AUTISM; CHILDHOOD; CHRONIC DISEASE; CORTICOSTEROID THERAPY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; ENTERITIS; FEVER; GENERAL PRACTITIONER; HEART DISEASE; HUMAN; HYPOTONIC HYPORESPONSIVE EPISODE; IMMIGRANT; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEDICAL CARE; ORGAN TRANSPLANTATION; PEDIATRICIAN; PEDIATRICS; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; REVACCINATION; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; VACCINATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; AGED; AUSTRALIA; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CLINICAL COMPETENCE; DRUG THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNIZATION; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PEDIATRICS; PHYSICIANS; TRANSPLANTS;

EID: 33750055732     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2006.00927.x     Document Type: Review

References (54)

1. Rural Health Education Foundation. Immunisation Update: Childhood Immunisation Schedule Changes as at 1/11/05. 2005. Available from: http://www.rhef.com.au/programs/511/511c.pdf [accessed 10 November 2005].
2. National Health and Medical Research Council. Meningococcal infections. In: The Australian Immunisation Handbook, 8th edn. Canberra: Australian Government Department of Health and Ageing, 2003; 192-202.
3. National Health and Medical Research Council. The Australian Immunisation Handbook, 8th edn. Canberra: Australian Government Department of Health and Ageing, 2003.
4. Royal College of Paediatrics and Child Health. Immunisation of the Immunocompromised Child. London: Royal College of Paediatrics and Child Health. 2002. Available from: http://www.rcpch.ac.uk/publications/recent_publications/ Immunocomp.pdf [accessed 22 July 2005].
5. National Health and Medical Research Council. Groups with special vaccination requirements. In: The Australian Immunisation Handbook, 8th edn. Canberra: Australian Government Department of Health and Ageing, 2003; 90-103.
6. Wise RP, Salive ME, Braun MM et al. Postlicensure safety surveillance for varicella vaccine. (Published erratum appears in JAMA 2000; 284: 3129). JAMA 2000; 284: 1271-9.
7. Diaz PS, Au D, Smith S et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991; 87: 166-70.
8. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 1996; 45 (RR-11): 1-36.
9. Macartney KK, Beutels P, McIntyre P, Burgess MA. Varicella vaccination in Australia. J. Paediatr. Child Health 2005; 41: 544-52.
10. Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995; 15: 455-60.
11. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. (Published erratum appears in MMWR Recomm. Rep. 2004; 53: 396). MMWR Recomm. Rep. 2000; 49 (RR-10): 1-125.
12. Stark K, Gunther M, Schonfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet 2002; 359: 957-65.
13. Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin. Infect. Dis. 2000; 30: 857-69.
14. Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr. Transplant. 2005; 9: 652-61.
15. National Health and Medical Research Council. Hepatitis B. In: The Australian Immunisation Handbook, 8th edn. Canberra: Australian Government Department of Health and Ageing, 2003; 145-59.
16. Casswall TH, Fischler B. Vaccination of the immunocompromised child. Expert Rev. Vaccines 2005; 4: 725-38.
17. American Academy of Pediatrics, Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2003.
18. Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. Pediatrics 2003; 112: 193-8.
19. Robinson MJ, Campbell F, Powell P, Sims D, Thornton C. Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Arch. Dis. Child. Fetal Neonatal Ed. 1999; 80: F69-71.
20. Clements CJ, ed. Supplementary Information on Vaccine Safety. Part 2: Background Rates of Adverse Events Following Immunization. Geneva: World Health Organization, Department of Vaccines and Biologicals, WHO/V&B/00.36. 2000. Available from: http://www.who.int/vaccines-documents/DocsPDF00/www562.pdf [accessed 10 November 2005].
21. Davidson N, Skull S, Chaney G et al. Comprehensive health assessment for newly arrived refugee children in Australia. J. Paediatr. Child Health 2004; 40: 562-8.
22. Strine TW, Barker LE, Mokdad AH, Luman ET, Sutter RW, Chu SY. Vaccination coverage of foreign-born children 19 to 35 months of age: findings from the National Immunization Survey, 1999-2000. Pediatrics 2002; 110: e15.
23. Schulte JM, Maloney S, Aronson J, San Gabriel P, Zhou J, Saiman L. Evaluating acceptability and completeness of overseas immunization records of internationally adopted children. Pediatrics 2002; 109: e22.
24. National Health and Medical Research Council. Catch-up vaccination. In: The Australian Immunisation Handbook, 8th edn. Canberra: Australian Government Department of Health and Ageing, 2003; 42-53.
25. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb. Mortal. Wkly Rep. 2004; 53: 177-8.
26. Mackenzie GA, Carapetis JR, Morris PS, Leach AJ. Current issues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children. J. Paediatr. Child Health 2005; 41: 201-8.
27. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 1983; 148: 131-7.
28. Fedson DS, Musher DM. Pneumococcal polysaccharide. In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th edn. Philadelphia, PA: W.B. Saunders, 2004; 529-88.
29. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N. Engl. J. Med. 2005; 352: 450-8.
30. Ferson MJ. Varicella vaccine in post-exposure prophylaxis. Commun. Dis. Intell. 2001; 25: 13-15.
31. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500-7.
32. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J. Med. Virol. 2003; 70 (Suppl. 1): S31-7.
33. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20: 1113-25.
34. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 2005; 191: 2002-7.
35. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 2005; 352: 2271-84.
36. Cosgrove SE, Fishman NO, Talbot TR et al. Strategies for use of a limited influenza vaccine supply. JAMA 2005; 293: 229-32.
37. Quach C, Piche-Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics 2003; 112: e197-201.
38. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). (Published erratum appears in MMWR Recomm. Rep. 2004; 53: 743). MMWR Recomm. Rep. 2004; 53 (RR-6): 1-40.
39. CDC Advisory Committee Recommends Expanded Influenza Vaccinations for Children. CDC Media release; 23 February 2006. Available from: http://www.cdc.gov/od/oc/media/pressrel/r060223.htm [accessed 20 April 2006].
40. National Health and Medical Research Council. Influenza. In: The Australian Immunisation Handbook, 8th edn. Canberra: Australian Government Department of Health and Ageing, 2003; 166-75.
41. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361: 1521-3.
42. Wood N. Immunisation adverse events clinics. NSW Public Health Bull. 2003; 14: 25-7.
43. Tinnion ON, Hanlon M. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev. 2000; (2): CD001478.
44. Rennels MB, Deloria MA, Pichichero ME et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105: e12.
45. Centers for Disease Control. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). (Published erratum appears in MMWR Morb. Mortal. Wkly Rep. 1997; 46: 706). MMWR Recomm. Rep. 1997; 46 (RR-7): 1-25.
46. Adverse Drug Reactions Advisory Committee (ADRAC). Extensive limb swelling and DTPa booster doses. Australian Adverse Drug Reactions Bulletin 2001; 20: 10. Available from: http://www.tga.gov.au/docs/pdf/aadrbltn/aadr0108. pdf [accessed 22 July 2005].
47. Centers for Disease Control. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2000; 49 (RR-13), 1-8.
48. Smeeth L, Cook C, Fombonne E et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004; 364: 963-9.
49. Madsen KM, Hviid A, Vestergaard M et al. A population-based study of measles, mumps, and rubella vaccination and autism. N. Engl. J. Med. 2002; 347: 1477-82.
50. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324: 393-6.
51. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr. Infect. Dis. J. 2000; 19: 1127-34.
52. Institute of Medicine, Stratton K, Gable A, Shetty P, McCormick M, eds. Immunization Safety Review. Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press, 2001.
53. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J. Child Psychol. Psychiatry 2005; 46: 572-9.
54. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS).The MMR Decision Aid.2005. Available from: http://www.ncirs.usyd.edu.au/decisionaid/index.html [accessed 10 November 2005].